19th LIPID CLUB AND THERAPEUTIC APHERESIS 2024 Edition
MIGHTY MEDIC Org.’s Advanced Clinical Major Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques, and Atherosclerosis Prevention Seminario Clinico Avanzato e formazione continua in Lipidologia Clinica, Disturbi del Metabolismo, Tecniche Terapeutiche Extracorporee e Prevenzione dell’Aterosclerosi Peschiera del Garda, Italy, April 18-19, 2024 FINAL PROGRAM
EVKEEZA (EVINACUMAB) AVAILABLE IN ITALY
There is a new reality in Italy that is likely to affect all of Europe, as was the case with Lomitapide. “Evinacumab is reimbursed as an adjunct to diet and other therapies aimed at reducing low-density lipoprotein cholesterol (LDL-C) for the treatment of adult and adolescent patients aged 12 years …
1st ILEP VIRTUAL SYMPOSIUM on CARDIOVASCULAR PREVENTION
16th LIPIDCLUB AND THERAPEUTIC APHERESIS
PICTURES OF THE EVENT October 7-8, 2021 – Verona 16th LIPID CLUB AND THERAPEUTIC APHERESIS Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques, and Atherosclerosis Prevention Verona, October 7-8, 2021Camera di Commercio, Industria Artigianato e Aricoltura di Verona Corso Porta Nuova, 96 – 37122 Verona VR …
FCS Announcement
We are collecting anonymised information on patients with familial chylomicronaemia syndrome (FCS)/multifactorial chylomicronaemia syndrome (MCS) as a service evaluation & quality improvement project. The project aims to improve understanding of natural history of FCS and to validate the use of FCS scoring algorithm. The project is approved by Manchester University …
E-ISFA 2020 Announcement
3rd Congress of the European Group – International Society for Apheresis (E-ISFA) Dresden, March 19 to 21, 2020 Congress Topics Recent progress in lipoprotein apheresis Homozygous familial hypercholesterolemia Lipoprotein(a) Competition with drugs Plasma exchange Immunoadsorption – indications, results, future perspectives Experience with extracorporeal therapy in children and during pregnancy Apheresis Registries …
LipidClub 2019
Brochure
The brochure on Familiar Hypercholsterolemia from Nutritional Medicine Institute of Austrian Academy (in German) Die Broschüre über familiäre Hypercholesterinämie von Österreichisches Akademisches Institut für Ernährungsmedizin (ÖAIE)
Cardiology Update Davos, Switzerland
Cardiology Update Davos, Switzerland 16-20 February 2019 Dear Colleagues It is my pleasure to announce the next Cardiology Update Course in Davos which belongs to the major meetings in the field of cardiology in Europe. As you know it is an Update Meeting endorsed by the ESC and a collaboration …
13th LipidClub & Therapeutic Apheresis – Interviews
Prof. Gerald Watts: Prof. Claudia Stefanutti Prof. Livia Pisciotta Prof. Widhalm
13th LipidClub and Therapeutic Apheresis – Streaming
Streaming – Part 1 Streaming – Part 2
13th LipidClub and Therapeutic Apheresis
Save the date! IAS 2018
2nd Congress of the European Group – International Society for Apheresis (E-ISFA)
12th Lipid Club and Therapeutic Apheresis
MightyMedic Workshop on Lipidology and Atherosclerosis – Genoa, Italy – 17 May 2017
HEART UK 31st Annual Medical & Scientific Conference
The Global Gathering For Orphan Drugs
The MIGHTY MEDIC Org FALL SCHOOL of CLINICAL LIPIDOLOGY
X Congresso Aferesi Terapeutica del Gruppo di Studio della Società Italiana di Nefrologia Napoli, 4 – 5 Novembre 2016 Centro Congressi Via Partenope
X Congresso Aferesi Terapeutica del Gruppo di Studio della Società Italiana di Nefrologia Napoli, 4 – 5 Novembre 2016 Centro Congressi Via Partenope
NOVEMBER 11-12, 2016 VIENNA, AUSTRIA
NOVEMBER 11-12, 2016 VIENNA, AUSTRIA
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial.
OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data …